Visceral Leishmaniasis Treatment, Italy
Authors:
Open Access
- 1 December 2003
- journal article
- Published by Centers for Disease Control and Prevention (CDC) in Emerging Infectious Diseases
- Vol. 9 (12) , 1617-1620
Abstract
First-line drug treatment was recorded in 573 immunocompetent patients with visceral leishmaniasis in Italy. In the past 12 years, the proportion of antimonial treatments decreased from 100% to 2.8%, while the proportion of amphotericin B treatments increased from 0% to 97.2%. The countrywide change in therapy is a response to both disease reemergence and increasing antimonial failure.Keywords
This publication has 13 references indexed in Scilit:
- Impact of Highly Active Antiretroviral Therapy on the Incidence of Visceral Leishmaniasis in a French Cohort of Patients Infected with Human Immunodeficiency VirusThe Journal of Infectious Diseases, 2002
- The increase in risk factors for leishmaniasis worldwideTransactions of the Royal Society of Tropical Medicine and Hygiene, 2001
- Miltefosine, an Oral Agent, for the Treatment of Indian Visceral LeishmaniasisNew England Journal of Medicine, 1999
- U.S. Food and Drug Administration Approval of AmBisome (Liposomal Amphotericin B) for Treatment of Visceral LeishmaniasisClinical Infectious Diseases, 1999
- Practical Guide for the Treatment of LeishmaniasisDrugs, 1998
- Epidemiologic Surveillance of Visceral Leishmaniasis in Sicily, ItalyThe American Journal of Tropical Medicine and Hygiene, 1997
- Epidemiological surveillance of leishmaniasis in HIV-1-infected individuals in ItalyAIDS, 1996
- Short-Course Treatment of Visceral Leishmaniasis with Liposomal Amphotericin B (AmBisome)Clinical Infectious Diseases, 1996
- Treatment of Mediterranean visceral leishmaniasis.1995
- Visceral leishmaniasis of adults in Sicily: A truce interrupted?Transactions of the Royal Society of Tropical Medicine and Hygiene, 1987